### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average but	urden
houre por rosponso	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response														
Name and Address of Reporting Person * Thornton Bruce				2. Issuer Name and Ticker or Trading Symbol Sonoma Pharmaceuticals, Inc. [SNOA]						5. 1	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O SONOMA PHARMACEUTICALS, INC., 645 MOLLY LANE, SUITE 150				3. Date of Earliest Transaction (Month/Day/Year) 01/14/2022						X Officer (give title below) Other (specify below)  COO					
(Street) WOODSTOCK, GA 30189				4. If Amendment, Date Original Filed(Month/Day/Year)					_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(Cit	(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						ired, Disposed of, or Beneficially Owned				
(Instr. 3)		2. Transaction Date (Month/Day/Year)	any	on Da	ate, if C		4. Securities Acq (A) or Disposed 6 (Instr. 3, 4 and 5)		of (D) Ow Tra	vned Follow ansaction(s)			Ownership of B	7. Nature of Indirect Beneficial Ownership	
				(Month/Day/Yea		i ear)	Code	e V A	(A) or (D)	Price	(Instr. 3 and 4)			` /	Instr. 4)
Reminder:	Report on a s	separate line for each	i class of securities	benericia				in this f	s who respor orm are not i s a currently	equired to	o respond	unless the		ed SEC 14	474 (9-02)
Reminder:	Report on a s	separate line for each	i class of securities	ochericia	,									ed SEC 14	74 (9-02)
1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction	Table II -  3A. Deemed Execution Date, if any	Derivati (e.g., pu 4. Transac Code	ive Se ts, cal	ecurities Ils, warr 5. Numbor Deriva Securitie	er ative	in this f display nired, Dispo options, co	orm are not use a currently used of, or Ben envertible securicisable and Date	equired to valid OME eficially Overities)  7. Title an of Underly Securities	o respond B control n wned and Amount lying	8. Price of Derivative Security	9. Number of Derivative Securities	f 10. Ownership Form of	11. Natur of Indirec Beneficia
1. Title of Derivative	2. Conversion	3. Transaction Date	Table II -  3A. Deemed Execution Date, if	Derivati (e.g., pu 4. Transac Code	ive Sets, cal	ecurities Ils, warr 5. Numbof Deriva	er ative s d (A) sed	in this f display nired, Dispo options, co 6. Date Exe Expiration 1	orm are not use a currently used of, or Ben envertible securicisable and Date	equired to valid OME eficially Overities)  7. Title and of Underly	o respond B control n wned and Amount lying	8. Price of Derivative	9. Number of Derivative Securities Beneficially Owned Following Reported Transactions	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect s) (I)	11. Natur of Indirec Beneficia Ownershi (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II -  3A. Deemed Execution Date, if any	Derivati (e.g., pu 4. Transac Code	ive Sets, cal	ecurities Ills, warr 5. Numbor Deriva Securitie Acquired or Dispos of (D) (Instr. 3,	er ative s d (A) sed 4,	in this f display nired, Dispo options, co 6. Date Exe Expiration 1	orm are not its a currently used of, or Bennvertible securicisable and Date //Year)	equired to valid OME eficially Overities)  7. Title an of Underly Securities	o respond B control n wned and Amount lying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indirec Beneficia Ownershi (Instr. 4)

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Thornton Bruce C/O SONOMA PHARMACEUTICALS, INC. 645 MOLLY LANE, SUITE 150 WOODSTOCK, GA 30189			COO			

## **Signatures**

Amy Thombly (Attorney in Fact)	01/14/2022
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options vest 10,000 each on 07/14/2022, 07/14/2023 and 07/14/2024, or upon change of control.

(2) The options were awarded and granted to Mr. Thornton for services performed.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.